Lexeo Therapeutics Stock (NASDAQ:LXEO)


ForecastFinancialsChart

Previous Close

$6.28

52W Range

$5.77 - $22.33

50D Avg

$7.92

200D Avg

$11.86

Market Cap

$205.34M

Avg Vol (3M)

$403.26K

Beta

-

Div Yield

-

LXEO Company Profile


Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

69

IPO Date

Nov 03, 2023

Website

LXEO Performance


LXEO Financial Summary


Dec 22Dec 21Dec 20
Revenue$654.00K$1.66M$518.48K
Operating Income$-60.51M$-50.64M$-4.59M
Net Income$-59.28M$-50.62M$-5.15M
EBITDA$-58.04M$-50.61M$-4.58M
Basic EPS$-2.40$-2.05$-0.21
Diluted EPS$-2.40$-2.05$-0.21

Fiscal year ends in Dec 22 | Currency in USD